Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHeiq Regulatory News (HEIQ)

  • There is currently no data for HEIQ

Restructuring and Delisting

22 Oct 2024 07:00

RNS Number : 0281J
HeiQ PLC
22 October 2024
 

This announcement contains inside information

 

HeiQ Plc

(the "Company")

Restructuring and Delisting

As detailed in the Company's trading update on 12 September 2024, with the exception of the Life Sciences business unit, the Company continues to face significant challenges in its core business units in Textiles, Flooring, and Antimicrobials due to ongoing curtailed demand. The industry wide consensus is that market conditions are only expected to recover towards the second half of 2025 and accordingly, the Company does not expect to see a significant improvement in performance of these core business units before then. In response, the Company has initiated a second restructuring plan aimed at reducing its costs by up to an additional 20% by the end of 2025. Key elements of this restructuring include:

· Reducing central organisation costs

· Relocating and streamlining of capabilities to hubs in Portugal, USA and Thailand

· Scaling back non-core elements of the Company's innovation pipeline and a reduction of associated corporate marketing activities

The Company has reviewed its strategic product portfolio within its core business units and is considering selective divestments, providing a commercially attractive offer or offers can be achieved. Any proceeds from divestments, should they materialize, would be used to finance HeiQ's three ventures (HeiQ AeoniQ, HeiQ GrapheneX and HeiQ Xpectra) and to accelerate the growth of its Life Sciences business unit.

Fundraising to scale-up Venture Units

· The Company is seeking substantial financing for its HeiQ AeoniQ venture, which, as reported in its recent trading update, recently met a key value-creating milestone by launching to market the world's first AeoniQ plastic-minimized sneaker with Hugo Boss. As previously announced, the Company embarked on a process to raise equity financing exclusively for the HeiQ AeoniQ subsidiary level.

· The Directors believe that the Company is close to meeting key milestones for its other two ventures, HeiQ GrapheneX and HeiQ Xpectra, and plans to accelerate their go-to-market strategies with additional external financing.

The Directors consider that the historically low valuation of HeiQ Plc limits the Company's ability to secure financing at HeiQ Plc level and complicates its efforts to raise funds for the various venture platforms at a subsidiary level.

Delisting

The Directors have concluded that the administrative, regulatory and cost burden associated with maintaining the Company's listing is, in their opinion, disproportionate to the benefits. In order to implement the restructuring programme detailed above, as well as to assist in the Company's financing efforts for its ventures, the Board has therefore concluded that it is necessary to cancel the listing of the Company's ordinary shares (the "Shares") on the Official List (equity shares (transition) category) of the Financial Conduct Authority ("FCA") and to cancel the admission to trading of the Shares on the Main Market for listed securities of the London Stock Exchange ("LSE") (the "Delisting"). The Directors believe that the Delisting would facilitate its restructuring programme, through a major reduction in annualized costs associated with being a listed company. Furthermore, the Directors believe that the Delisting would greatly assist the Company to raise financing in the private markets for its venture platforms at higher valuations and enable their growth and value creation for Company's shareholders.

As a company listed on the equity shares (transition) category, the Company is not required to obtain the approval of shareholders for the Delisting but is required under UK Listing Rule 21.2.17 to give at least 20 business days' notice of the intended cancellation.

Accordingly, HeiQ has requested that (i) the FCA cancel the listing of the Shares on the Official List of the FCA, and that (ii) the LSE cancels the admission to trading of the Shares on the Main Market for listed securities of the LSE. It is anticipated that the Delisting will become effective from 08:00 a.m. (London time) on 19 November 2024. Investors holding Shares following the Delisting will remain a shareholder of HeiQ plc and continue to be entitled to exercise all of the rights attaching to the Shares and their attention is drawn to the paragraph below entitled "Dealing Arrangements",

The Company intends to publish its Annual Accounts for the 18-month period ending 30 June 2024 by 31 October 2024, as required by the UK Listing Rules. The Company's 2024 Annual General Meeting is expected to take place in November 2024, further details of which will be announced in due course.

Dealing Arrangements

Following the Delisting, the Shares will be admitted to trading on the JP Jenkins securities matching platform with effect from 20 November 2024.

JP Jenkins provides a securities matching venue for unlisted or unquoted assets in companies, enabling shareholders and prospective investors to buy and sell shares on a matched bargain basis. JP Jenkins is a trading name of InfinitX Limited and Appointed Representative of Prosper Capital LLP (FRN453007).

Shareholders wishing to trade Shares on the JP Jenkins platform can place orders through their stockbroker. Trades will be conducted at a level that JP Jenkins is able to match a willing seller and a willing buyer. Trades can be conducted, and limits can be accepted, during normal business hours. Shareholders or potential investors can place limits via their existing UK regulated stockbroker.

The indicative pricing for the ordinary Shares (ISIN: GB00BN2CJ299), as well as the transaction history, will be available on the JP Jenkins website at (https://jpjenkins.com/company/HeiQ/).

The provision of the matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility, the composition of the Company's register of members and the associated costs to the Company and its shareholders.

For further information, please contact: investors@heiq.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDDFLFLZBLZFBV
Date   Source Headline
18th Nov 20247:00 amRNSDirector/PDMR Shareholding
14th Nov 20247:00 amRNSUpdate on Delisting and Potential Capital Raise
31st Oct 20247:01 amRNSNotice of AGM
31st Oct 20247:00 amRNSResults for 18-month period ended 30 June 2024
24th Oct 202411:26 amRNSHolding(s) in Company
22nd Oct 20247:00 amRNSRestructuring and Delisting
18th Sep 202411:45 amRNSHolding(s) in Company
16th Sep 20249:03 amRNSDirector/PDMR Shareholding
12th Sep 20247:00 amRNSTrading Update
16th Jul 20247:00 amRNSHeiq AeoniQ Capital Raising
30th May 20247:00 amRNSChange of Auditor
22nd Apr 20247:00 amRNSHeiQ Synbio Secures Ecolab Contract Win
16th Apr 20242:17 pmRNSHolding(s) in Company
28th Mar 20247:00 amRNSUnaudited Interim Results
18th Mar 202412:41 pmRNSHolding(s) in Company
15th Mar 20247:00 amRNSHolding(s) in Company
14th Mar 20241:23 pmRNSCompletion of Fundraising, PDMR & Audit Update
13th Mar 20242:26 pmRNSResult of General Meeting
12th Mar 20247:00 amRNSBoard Changes
23rd Feb 20247:00 amRNSResult of Retail Offer
16th Feb 20247:00 amRNSResult of Placing
15th Feb 20245:49 pmRNSRetail Offer
15th Feb 20245:46 pmRNSAcquisition, Fundraising, Trading Update & GM
6th Dec 20232:46 pmRNSAgreed Changes to Concert Party
4th Dec 20237:00 amRNSDirector/PDMR Dealing
1st Dec 20233:04 pmRNSResult of General Meeting
30th Nov 20237:06 amRNSStatement Confirming Settlement
27th Nov 20237:00 amRNSBoard Appointment
8th Nov 20237:00 amRNSNotice of General Meeting
3rd Nov 20239:14 amRNSHolding(s) in Company
3rd Nov 20237:05 amRNSHolding(s) in Company
31st Oct 20237:43 amRNSFiling of Annual Report & Restoration of Trading
31st Oct 20237:30 amRNSRestoration - HEIQ PLC
30th Oct 20237:01 amRNSInterim Results
30th Oct 20237:00 amRNSResults for year ended 31 December 2022
23rd Oct 20237:00 amRNSNotice of Results and Audit Update
29th Sep 20237:00 amRNSAccounts Update
6th Jul 20237:00 amRNSMAS Holdings invests in HeiQ AeoniQ
29th Jun 20232:16 pmRNSResult of AGM
29th Jun 20237:00 amRNSAGM Statement
6th Jun 20237:00 amRNSNotice of AGM
2nd May 20237:44 amRNSTemporary Suspension of Trading in Ordinary Shares
27th Apr 20233:55 pmRNSTemporary Suspension
13th Jan 20232:09 pmRNSUpdate re. admission of Consideration Shares
12th Jan 20237:00 amRNSCompletion of Acquisition
10th Jan 20237:00 amRNSDirector / PDMR Dealing
6th Jan 20237:00 amRNSDirector / PDMR Dealing
5th Jan 20237:03 amRNSDirector/PDMR Shareholding
4th Jan 20237:00 amRNSTrading Update and Acquisition
14th Dec 20227:00 amRNSIncreased interest in HeiQ Chrisal to 71%

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.